Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial
2016 Gastrointestinal Cancers SymposiumSimron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).
Related Videos
Somnath Mukherjee, MD, on Esophageal Adenocarcinoma: Results of the NEOSCOPE Trial
Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based ch...
Toshihiko Doi, MD, PhD, on Esophageal Carcinoma: Study Results From KEYNOTE-028
Toshihiko Doi, MD, PhD, of Japan’s National Cancer Center Hospital East, discusses updated results on pembrolizumab for advanced esophageal cancer (Abstract 7).
Jonathan R. Strosberg, MD, on Neuroendocrine Tumors: Results of the NETTER-1 Trial
Jonathan R. Strosberg, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses progression-free survival, radiographic response, and preliminary overall survival find...
Yoon-Koo Kang, MD, PhD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Trial Results for T-DM1 vs a Taxane
Yoon-Koo Kang, MD, PhD, of the Asan Medical Center, discusses findings from this multicenter, phase II/III study of ado-trastuzumab emtansine vs a taxane in patients with previousl...
Dung T. Le, MD, on Gastric or Gastroesophageal Junction Cancer: Results From the CheckMate-032 Trial
Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, discusses study findings on the safety and activity of nivolumab monotherapy in advanced an...
